Prevalence of comorbidities in hospitalised patients with severe respiratory viral infections
| Geographic region | COVID-19 | Influenza | SARS | MERS | ||
| USA | China | Italy* | USA | Canada | Middle East, Europe | |
| Total number | 178 | 416 | 1043 | 3271 | 144 | 637 |
| Diabetes mellitus | 28.3% | 14% | 17.3% | --- | 11% | 51% |
| Hypertension | 49.7% | 30.5% | 48.8% | --- | --- | 49% |
| Cardiovascular disease | 27.8% | 14.7% | 21.4% | 45.6% | 8% | 31% |
| Obesity | 48.3% | --- | --- | 39.3% | --- | --- |
| Chronic lung disease | 34.6% | 2.9% | 4.0% | 34.5% | 1% | |
| Malignancy or immunocompromised | 9.6% | 2.2% | 7.8% | 17.0% | 6% | |
| Source (reference) | CDC COVID-Net, Garg et al 78 | Shi et al 7 | Grasselli et al 79 | CDC FluServ-Net80 | Booth et al 81 | Badawi and Ryoo73 |
*Only including patients in the intensive care unit.
CDC, Centre for Disease Control and Prevention; MERS, Middle East respiratory syndrome; SARS, severe acute respiratory syndrome.